文献速递胸部介入CT

CT引导微波消融治疗肉瘤大体积肺转移

CT-guided microwave ablation for large inoperable pulmonary metastases from sarcoma: a case series.
PubMed 文献 · Br J Radiol · 2026-01-01

回顾性评估经皮CT引导微波消融治疗肉瘤来源大体积不可手术肺转移的可行性、疗效与安全性。纳入15例患者共17个病灶,平均直径7.6±1.7 cm。结果显示中位总生存39个月,完全缓解4个,部分缓解11个,无治疗相关死亡。

要点

  • 大体积肉瘤肺转移也可尝试CT引导微波消融
  • 气胸最常见,发生率20.8%,阅片报告需留意术后气胸
  • 根治性消融较姑息性消融局部无进展生存更优

核心结论

  • CT引导微波消融治疗肉瘤来源大体积不可手术肺转移安全有效,可作为替代治疗选择。

研究设计与样本

  • 回顾性病例系列研究,评价经皮CT引导微波消融治疗大体积不可手术肉瘤肺转移。
  • 纳入2011年1月1日至2018年5月1日15例肉瘤患者共17个不可手术肺转移灶。
  • 患者中位年龄35岁,男性9例,女性6例,平均病灶大小7.6±1.7 cm,范围5.0-10.8 cm。
  • 中位随访24.6个月,范围1.6-65.8个月,所有患者均签署知情同意书并经机构审查委员会批准。

关键影像表现/征象

  • 原文本提供影像征象描述有限,17个病灶平均直径7.6±1.7 cm,最大10.8 cm,属于大体积肺转移。
  • 消融后评价完全缓解4个肿瘤,部分缓解11个肿瘤,2个肿瘤出现疾病进展。

诊断标准与关键数值

  • 完全缓解率为23.5%(4/17),部分缓解率为64.7%(11/17),疾病进展率为11.8%(2/17)。
  • 1年、2年和3年总生存率分别为78.6%、69.8%和50.9%。
  • 中位总生存时间为39个月,95%CI为18.2-59.8个月。

临床应用与阅片要点

  • 对于肉瘤来源大体积不可手术肺转移,CT引导微波消融可作为局部治疗选择之一。
  • 术后影像随访需重点关注气胸,本组气胸发生率为20.8%。
  • 中位住院时间5天,消融治疗后恢复较快。

局限性

  • 研究为回顾性病例系列设计,样本量较小。
  • 原文未报告多中心信息,研究设计本身存在回顾性偏倚可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVES: This study aimed to retrospectively evaluate the feasibility, efficacy and safety of percutaneous computed tomography (CT)-guided microwave ablation (MWA) for the treatment of large inoperable pulmonary metastases from sarcoma.

METHODS: The study was approved by the institutional review board, and informed consent was obtained from all patients. From January 1, 2011, to May 1, 2018, 15 patients with sarcoma (9 males and 6 females; median age 35 years) with 17 large inoperable pulmonary metastases from sarcoma (mean size, 7.6 ± 1.7 cm; range, 5.0-10.8 cm) received percutaneous CT-guided microwave ablation. The treatment efficacy, complications and overall survival were evaluated.

RESULTS: The median follow-up was 24.6 months (range 1.6-65.8 months). Complete response was achieved in 4 tumors (23.5%), partial response in 11 tumors (64.7%), while 2 tumors (11.8%) demonstrated disease progression. The 1-, 2- and 3-year overall survival rates were 78.6%, 69.8% and 50.9%, respectively. The median overall survival time was 39 months (95% CI 18.2-59.8 months). Curative ablation was associated with significantly improved local progression-free survival compared with palliative ablation (median LPFS: not reached vs 17.09 months; HR 4.913, 95% CI: 1.039-23.24, P = .046). No treatment-related death occurred. Pneumothorax was the most common complication with an incidence of 20.8%(n = 5). The median hospital stay was 5 days.

CONCLUSION: CT-guided microwave ablation appears to be a safe and effective treatment for large inoperable pulmonary metastases from sarcoma.

ADVANCES IN KNOWLEDGE: CT-guided MWA can be used as an alternative treatment for patients with large inoperable lung metastases from sarcoma with potential clinical benefits.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Xie, Cao, Shen, et al. CT-guided microwave ablation for large inoperable pulmonary metastases from sarcoma: a case series. Br J Radiol. 2026. PMID: 42258617. doi:10.1093/bjr/tqag088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。